SCHEMBL23933116

SCHEMBL23933116

CC(C)(C)OC(=O)NCCCC[C@H](NC(=O)CNC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KLK7 P49862 2/20 0.53
▸ KLK5 Q9Y337 2/20 0.53
▸ TLR2 O60603 1/20 0.51
▸ TLR1 Q15399 1/20 0.51
▸ MAPT P10636 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ ITGB3 P05106 1/20 0.47
▸ ITGA2B P08514 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ RECQL P46063 1/20 0.45
▸ PAX8 Q06710 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ ABCB1 P08183 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29768941 1.00 KLK7 (0.53) KLK7KLK5TLR2TLR1MAPT
SCHEMBL23933117 1.00 KLK7 (0.53) KLK7KLK5TLR2TLR1MAPT
SCHEMBL30631751 0.92 KLK7 (0.54) KLK7KLK5TLR2TLR1MAPT
SCHEMBL2289677 0.92 KLK7 (0.54) KLK7KLK5TLR2TLR1MAPT
SCHEMBL2289683 0.92 KLK7 (0.54) KLK7KLK5TLR2TLR1MAPT
SCHEMBL31011377 0.92 KLK7 (0.54) KLK7KLK5TLR2TLR1MAPT
SCHEMBL14064950 0.92 KLK7 (0.54) KLK7KLK5TLR2TLR1MAPT
SCHEMBL20529969 0.92 KLK7 (0.50) KLK7KLK5TLR2TLR1MAPT
SCHEMBL28339679 0.92 KLK7 (0.50) KLK7KLK5TLR2TLR1MAPT
SCHEMBL16870063 0.91 KMT2A (0.53) KLK7KLK5TLR2TLR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4271387-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF Immunext, Inc. (US) 2023-11-08 — — EP disclosed
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 — — US disclosed
CN-116096413-A Anti-human VISTA antibodies and uses thereof 伊穆奈克斯特股份有限公司 2023-05-09 — — CN disclosed
EP-4136118-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF Immunext, Inc. (US) 2023-02-22 — — EP disclosed
WO-2022150637-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF IMMUNEXT, INC. (US) 2022-07-14 — — WO disclosed
WO-2021216913-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT, INC. (US) 2021-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A KLK7 3771/4885KLK5 2745/4885TLR2 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback